Norbert VEY
MD
-
General Director at Institut Paoli Calmettes | Professor of Hematology at Aix-Marseille University
AMU, IPC
The new immunotherapy antibodies currently developed by biotech companies from Marseille reflect the teams' dynamism and the extraordinary local potential.
As a clinician involved for several years in cancer immunotherapy, in particular in leukemias, the creation of Marseille Immunopôle is a significant step forward. With the experience of the development of anti-KIR antibodies, we have shown the creatity and efficiency of the Marseille’s network in the field of immuno-oncology: from basic (CIML) to clinical research (IPC-SIRIC Marseille) through translational (CRCM) and industry research (Innate Pharma).
MI will enable the development of original and highly innovative approaches in immunotherapy, based on these three pillars. New molecules currently developed by biotech companies from Marseille reflect the teams’ dynamism and the extraordinary local potential.
#clinique #rechercheHave a look on our testimonies
Veracyte (formerly HaliodDx) is a key player in the MI ecosystem that allows both personalized immunotherapies utilization and acceleration of their development.
Vincent FERT
Veracyte
Being primarily centred on the patient, my work combines the short-term management of the disease and the long-term of clinical research.
Catherine FARNARIER
AP-HM
As such, we are involved in the Marseille immunology biotope
Michel MANCIS
Protisvalor
MI-mAbs allows researchers to validate the therapeutic potential of their discovery and permits industrials to focus their efforts on the most promising drug candidate
Francois ROMAGNÉ
AMU, MI-mAbs
your commitment to MI